Anondita Medi. moves to reshape its capital structure

The final valid subscription was approximately 1.89 times: 18,10,742 shares were applied for against 9,58,166 shares offered, while all 9,58,166 shares were allotted. This implies an aggregate allotment rate of 52.92%, or roughly 1 share allotted for every 1.89 shares applied. These are derived from the valid-application figures in the Basis of Allotment. ^[1]

Including applications later classified as technical or partial rejections, the gross application figure was 18,31,470 shares, equivalent to 1.91 times the issue size. ^[1]

The Letter of Offer had originally proposed an entitlement of 97 rights shares for every 1,831 shares held, equivalent to 5.30% of existing holdings. ^[1]

Comparison: the 97:1,831 ratio was the initial entitlement ratio; the 52.92% figure was the subsequent allotment rate against valid applications. They are not directly comparable because their denominators differ. The oversubscription did not change the original entitlement ratio; it determined how additional applications were scaled in the final allotment.

Latest allotment split: the promoter group holds 62.40% of Anondita Medi.’s equity, while public shareholders hold 37.60% as of Q4 FY26. Promoter encumbrance was 0.00% of promoter holdings.

The net observed impact versus the prior recorded shareholding level is therefore a 0.61 percentage-point increase in the promoter group’s ownership, matched by a 0.61 percentage-point reduction in public ownership. This is a change in ownership percentages; it does not, by itself, establish that the movement was caused solely by the referenced issuance.

The issuance-specific allotment between promoters and public shareholders, and the promoter percentage immediately before that issuance, are not reported in the cited records. Accordingly, the precise issuance-driven dilution or accretion cannot be isolated beyond the Q2-to-Q4 FY26 shareholding movement.

Verdict: Anondita’s rights issue was priced at Rs 950 per share, with a record date of 2 September 2026 ^[1]. However, the discount to the prevailing market price cannot be quantified because the 2 September market close is not reported in the cited material. No comparable rights-issue pricing terms for the named peer companies are available for FY25-FY26, so a defensible peer ranking is not possible.

Pricing comparison

The calculation required is:

Discount = (market price on 2 September 2026 − Rs 950) / market price on 2 September 2026

Thus, the issue can presently be described only as a fixed-price rights issue, not as one offered at a quantified discount or premium to the market. The allotment filing records applications for 18,31,470 shares against 9,58,166 shares offered, but the company itself cautioned that subscription levels should not be taken as indicative of the market price or business prospects ^[1]. Accordingly, strong subscription cannot substitute for the missing market-price comparison.

Comparability limitation: The named comparison set does not establish a comparable mid-cap healthcare-service peer group in the cited evidence, and news or broker coverage for FY25-FY26 was unavailable. Any conclusion that Anondita used a deeper or shallower discount than similar healthcare providers would therefore be unsupported.